Acumen Pharmaceuticals (ABOS) EBITDA (2020 - 2026)

Acumen Pharmaceuticals' EBITDA history runs 7 years deep, the most recent figure standing at -$20.8 million for Q1 2026.

• In Q1 2026, EBITDA rose 27.61% year-over-year to -$20.8 million; the TTM figure through Mar 2026 stood at -$113.3 million (up 2.43% YoY), while the FY2025 annual figure was -$121.2 million, down 18.03% from the prior year.
• EBITDA came in at -$20.8 million for Q1 2026 at Acumen Pharmaceuticals, up from -$25.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.7 million in Q1 2022 to a low of -$40.9 million in Q2 2025.
• A 5-year average of -$20.0 million and a median of -$15.7 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 199.39% in 2022 and soared 33.29% in 2025, its largest moves.
• Acumen Pharmaceuticals' EBITDA stood at -$12.7 million in 2022, then fell by 23.9% to -$15.7 million in 2023, then sank by 140.62% to -$37.7 million in 2024, then jumped by 33.29% to -$25.2 million in 2025, then rose by 17.35% to -$20.8 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$20.8 million, -$25.2 million, and -$26.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison